Hansoh Pharmaceutical has announced that the new drug approval (NDA) for its once‑weekly GLP‑1/GIP dual receptor agonist, olatorepatide (HS‑20094), has been accepted by the National Medical Products Administration (NMPA) in its China homeland. The application is for the long‑term management of weight in adults with obesity or overweight. This regulatory milestone follows positive Phase III results presented in March 2026, which demonstrated a mean weight reduction of up to 19.3% from baseline after 48 weeks of treatment, with 97.2% of patients achieving at least a 5% weight loss.

Notably, the candidate showed a favourable gastrointestinal tolerability profile, with nausea and vomiting rates averaging below 10% and 5% respectively – figures that compare advantageously to other GLP‑1‑based dual agonists. In June 2025, Hansoh granted Regeneron exclusive global rights (excluding Greater China) to develop and commercialise the asset, underscoring its international potential in a market with significant unmet need.

PharmCube's NextBiopharm® database shows that olatorepatide achieves much earlier a weight-loss efficacy comparable to that of Eli Lilly's tirzepatide (20.2% at week 72; 21.9% at week 112). Click here to request a free trial for NextBiopharm®.